[Therapy of peripheral arterial occlusive disease with special reference to prostaglandins].
Therapy of chronic arterial occlusive disease primarily includes evaluation and treatment of risk factors as prophylaxis for preventing progression of arteriosclerosis. When patients suffer from claudication walking exercise is the therapy of choice. Only in cases with severe claudication (walking distance under 100 m) and rest pain or ischemic ulcers reopening procedures are necessary. Bypass surgery is supported by the different transluminal angioplasty techniques, which are suited even for older and multimorbid patients. A pharmacological treatment of peripheral arterial occlusive disease should be introduced only for preventing progression of the disease or re-occlusions following surgery or angioplasty or in those cases in whom reopening techniques are not possible or not successful. Here prostaglandin E1 has been proven to be effective in many clinical trials. The combination of surgery, angioplasty and pharmacological treatment allows to avoid major amputations in most patients with critical limb ischemia.
Creutzig
A
A
Abteilung Angiologie, Medizinischen Hochschule Hannover.
D000527:Alprostadil / Q000627:therapeutic use; D000800:Angioplasty, Balloon; D001157:Arterial Occlusive Diseases / Q000628:therapy*; D001161:Arteriosclerosis / Q000628:therapy; D003131:Combined Modality Therapy; D004691:Endarterectomy; D005081:Exercise Therapy; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007383:Intermittent Claudication / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012008:Recurrence
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D000527:Alprostadil
Therapie der peripheren arteriellen Verschlusskrankheit mit besonderer Berücksichtigung der Prostaglandine.